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INTRODUCTION
Theobromine, formerly known as a bitter alka-
loid of the cacao plant (3,29), is a caffeine derivative 
and metabolite found primarily in chocolate. It may 
occur in the body as it is a product of the human me-
tabolism of caffeine, which is metabolised in the liv-
er into 10% theobromine, 4% theophylline, and 80% 
paraxanthine (27). In the liver, theobromine is me-
tabolized into xanthine and subsequently into meth-
yluric acid (10). Theobromine is highly fat soluble 
with peaking in the plasma 1–2 h after ingestion (21).
Like other methylated xanthine derivatives, 
theobromine is both a competitive nonselective 
phosphodiesterase inhibitor (13), which raises intra-
cellular cAMP, activates PKA, inhibits TNF-alpha 
(11,19) and leukotriene synthesis (22), and reduces 
inflammation and innate immunity (22) and nonse-
lective adenosine receptor antagonist (12). As a phos-
phodiesterase inhibitor, theobromine helps prevent 
the phosphodiesterase enzymes from converting the 
active cAMP to an inactive form (24). 
As an adenosine receptor antagonist, theobro-
mine appears to have equal affinity for A1 compared 
to A2A receptors, while caffeine shows a slightly lower 
affinity for A1 receptors (25). Theobromine has one 
fifth the stimulant effect of caffeine, but with a lon-
ger half-life in the body (21).
ABSTRACT
Five-stage synthetic scheme for obtaining of N-substituted 1-benzyltheobromine-8-thioglicolacetamides 
was described. The intermediate compound 1-benzyl-8-bromotheobromine was synthesized using aliquat 
336 as phase transfer catalyst in very good yield. Five amide derivatives of 1-benzyltheobromine-8-thiogli-
colyc acid were obtained in yields of 61 to 81%. The structures of the studied compounds were established 
by FTIR, 1H NMR spectral data. In order to estimate the drug-likeness of compounds 7a-e, a theoretical cal-
culation of some molecular descriptors was made using two approaches: the Lipinski’s Rule of Five limita-
tions and the OSIRIS Property Explorer evaluation score. The comparison of the calculated results indicate 
that only one compound violates the Lipinski’s Rule of Five parameters – 7c, which makes it unsuitable for 
further structural optimizations. On the other hand compound 7e shows the  highest drug like properties 
with Fragment Based Druglikeness score of 2.58 and total Drug score of 0.43 which are better than the same 
scores of parent compound theobromine.
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As a phosphodiesterase inhibitor, theobromine 
inhibits phosphodiesterase (PDE) non-selectively 
and also shows adverse effects on the cardiovascu-
lar and central nervous systems (1,5,8,15). It is of in-
terest to investigate the structure–activity relation-
ships of alkylxanthines. During this investigation 
has been found that the alkyl substitution at N1 leads 
to increased selectivity to PDE4 inhibition. In addi-
tion, introduction of a benzyl group at the N1 po-
sition results in a potent and selective PDE4 inhib-
itor, with the most potent PDE4 inhibitory activity 
among xanthine derivatives known to be PDE4 in-
hibitors (26). 
These results determined the purpose of our 
work to obtain amide derivatives of 1-benzyltheo-
bromine-8-thioglycolic acid and to determine their 
drug-like properties as preliminary information for 
their further application as potential PDE inhibitors.
MATERIAL AND METHODS
Apparatuses and devices
The used chromatographic system for TLC con-
trol and purity elucidation is based on an alimunium 
sheets Silica gel F254 (Merck, Darmstadt, Germa-
ny), using the following mobile phases: Phase 1: 25% 
NH4OH/Acetone/CHCl3/CH3CH2OH (1/3/3/4) and 
Phase 2: H2O/n-butanol/CH3COOH (5/4/1), with de-
tection at UV 254 nm. Yields were calculated for pu-
rified products. The IR spectra 400 – 4000cm-1 were 
recorded on a Shimadzu FT-IR Spectrometer in KBr 
pellets. The 1H-NMR spectra were registered at 100 
MHz on spectrometer Bruker 100 (Faenlanden, Swit-
zerland) as  (ppm) relative to TMS as internal stan-
dard and the coupling constants (J) are expressed in 
Hertz (Hz). All NH protons were D2O exchangeable. 
All names were generated by using ACD/Name Ver-
sion 2.51 (9). 
The starting materials were of commercially 
available research – grade chemicals. (Merck, Darm-
stadt, Germany). Commercial aliquat 336 was used 
as catalysts.
Synthesis of 8-bromotheobromine (2)
The bromination of theobromine was carried 
out in a four-neck round bottom flask (total volume 
1000 ml) placed in a heating mantle with a mechan-
ical stirrer and temperature controller. The centre 
neck was fitted with mechanical stirrer whose speed 
was maintained at 700 rpm. A thermometer for tem-
perature control and a Liebig condenser for reflux 
were inserted into two of the side necks. The other 
side neck allowed sampling of the reaction mixture. 
A 0.1 mol of theobromine were dissolved in 200 ml 
acetic acid. 29 ml of 62% HBr were added to the solu-
tion. The temperature was raised up to 80o-85oC. Af-
ter complete homogenization of the reaction mixture 
25 ml 30% hydrogen peroxide were added dropwise. 
The reaction mixture was left under the same condi-
tions for 4 hours, then cooled to room temperature 
and decolourized with sodium sulphite. The color-
less solution was poured into 400 ml ice water and 
kept for 12 hours at 4oC. The separated precipitate 
of 8-bromotheobromine was filtered under reduced 
pressure and recrystallised from ethanol. Yield – 
23.2g (85%), m.p. – above 300oC. The structure of the 
compound was confirmed by IR spectral analysis.
Synthesis of 1-benzyl-8-bromotheobromine (3)
In a round bottom flask 0.04 mol of 8-bro-
motheobromine and 0.06 mol of finely powdered 
KOH were suspended in 50 ml benzyl chloride. A 
half milliliter of the catalyst aliquot 336 was added 
and the temperature was raised under a glycerin bath 
up to 150oC for one hour. The reaction was controlled 
by TLC and stopped after exhaustion of the starting 
compounds. After cooling a volumetric precipitate of 
1-benzyl-8-bromotheobromine was formed. The ob-
tained crystals were filtered and washed with petro-
leum ether. After drying out the crystals were pro-
cessed with 50 ml of water and filtered again. The 
filtrate was evaporated and the benzyl chloride resi-
due was regenerated. The yield after purification was 
98%, m.p. – 185-187oC. The structure of the com-
pound was confirmed by IR spectral analysis.
Synthesis of 1-benzyltheobromine-8-thioglico-
lic acid (4)
The reaction was carried out in reactor of 500 
ml capacity which was equipped with mechanical 
stirrer (speed was maintained at 700 rpm) and a re-
flux condenser was placed on top of the reactor in or-
der to prevent the escape of volatile compounds. The 
reaction mixture is water: ethanol = 40:60. 0.06 mol 
sodium hydroxide was preliminary solved in the wa-
ter phase. Afterwards 0.03 mol of thioglicolic acid 
were added. The ethanol and the 0.029 mol of 1-ben-
zyl-8-bromotheobromine were added and the re-
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action mixture was heated under reflux for 1 and a 
half hour. The reaction mixture is filtered when hot 
and acidified with previously prepared solution of 1 
part acetic acid and 4 parts water, with pH about 2. 
A white precipitate was obtained, which was filtered 
and dissolved in 5% sodium hydrogen carbonate. 
The insoluble sodium salt of the unreacted 1-ben-
zyl-8-bromotheobromine was formed. The mixture 
was filtered and the filtrate was acidified with c. HCl 
to pH about 3. The separated precipitate was filtered 
under vacuum and dried. Yield –81%, m.p. – 193 
– 194 C. The structure of the compound was con-
firmed by IR spectral analysis and its purity was elu-
cidated by TLC.
Synthesis of methyl ester of 1-benzyltheobro-
mine-8-thioglicolic acid (5)
Esterification of 1-benzyltheobromine-8-thio-
glicolic acid was performed according to the clas-
sical esterification (23) by interaction of the corre-
sponding acid and alcohol in presence of sulfuric 
acid. The reaction was carried out in a round bot-
tom flask in excess of anhydrous methanol (300 ml). 
The flask was placed in a cooling bath and 30 ml of 
H2SO4 were added in aliquots. After its full addition 
17g of 1-benzyltheobromine-8-thioglicolic acid were 
added and the mixture was boiled under reflux for 4 
hours. The process was monitored by TLC until ex-
haustion of the initial thioglicolic acid. After the end 
of the reaction the mixture was filtered and a triple 
amount of water was added to the filtrate. The mix-
ture was kept for 24 hours at 12oC until formation of 
a volumetric precipitate, which was filtered and puri-
fied by re-crystallization from ethanol. Yield –86.1%, 
m.p. – 143 – 144 C. The structure of the compound 
was confirmed by IR spectral analysis and its purity 
was elucidated by TLC.
General procedure for the synthesis of amides 
of 1-benzyltheobromine-8-thioglicolic acid (7a-e)
In a conical flask 0.005 mol of methyl ester of 
1-benzyltheobromine-8-thioglicolic acid and 0.01 
mol of the corresponding amine (6a-e) was mixed 
and placed in glycerin bath at 115o – 130oC respec-
tively. The process was monitored by TLC until ex-
haustion of the initial compounds. The obtained 
crystals were purified accordingly by re-crystalliza-
tion from ethanol and/or ether.
The IUPAC names of the newly synthesized 
compounds together with the interpretation of their 
IR and 1H NMR spectra are presented below; the 
chemical structures are presented in Fig. 3, the rele-
vant melting points and the individual yields are pre-
sented in Table 1.
2-(1-benzyl-3,7-dimethyl-2,6-dioxo-2,3,6,7-tet-
rahydro-1H-purin-8-ylthio)-N-cyclohexylacetamide 
(7a): IR (KBr):  1725, 1705, 1685, 1605, 1558;1H NMR 
(100 MHz, DMSO-d6) , ppm: 9.40 (s, 1H, NH), 7.24-
7.36 (m, 5H, C6H5), 4.80 (s, 2H, N1-CH2), 3.48 (s, 3H, 
N3-CH3), 3.70 (s, 2H, S-CH2), 3.82 (s, 3H, N7-CH3), 
1.36-3.85 (m, 11H, C6H11).
2-(1-benzyl-3,7-dimethyl-2,6-dioxo-2,3,6,7-tet-
rahydro-1H-purin-8-ylthio)-N-cyclohexyl-N-ethyl 
acetamide (7b): IR (KBr):  1720, 1702, 1680, 1552;1H 
NMR (100 MHz, DMSO-d6) , ppm: 7.24-7.36 (m, 
5H, C6H5), 4.80 (s, 2H, N1-CH2), 3.45 (s, 3H, N3-
CH3), 3.70 (s, 2H, S-CH2), 3.80 (s, 3H, N7-CH3), 1.40-
3.80 (m, 22H, 2xC6H11).
2-(1-benzyl-3,7-dimethyl-2,6-dioxo-2,3,6,7-tet-
rahydro-1H-purin-8-ylthio)-N,N-dicyclohexylacet 
amide (7c): IR (KBr):  1715, 1702, 1684, 1554;1H 
NMR (100 MHz, DMSO-d6) , ppm: 7.24-7.36 (m, 
5H, C6H5), 4.80 (s, 2H, N1-CH2), 3.46 (s, 3H, N3-
CH3), 3.70 (s, 2H, S-CH2), 3.80 (s, 3H, N7-CH3), 3.26 




acetamide (7d): IR (KBr):  1716, 1702, 1680, 1555;1H 
NMR (100 MHz, DMSO-d6) , ppm: 7.24-7.36 (m, 
5H, C6H5), 4.80 (s, 2H, N1-CH2), 3.45 (s, 3H, N3-
CH3), 3.70 (s, 2H, S-CH2), 3.80 (s, 3H, N7-CH3), 3.26 




2-yl)methyl)acetamide (7e): IR (KBr):  1720, 1701, 
1684, 1595, 1552;1H NMR (100 MHz, DMSO-d6) , 
ppm: 9.40 (s, 1H, NH), 7.24-7.36 (m, 5H, C6H5), 4.80 
(s, 2H, N1-CH2), 3.40 (s, 3H, N3-CH3), 3.70 (s, 2H, 
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S-CH2), 3.81 (s, 3H, N7-CH3), 3.13 (s, 2H, NH-CH2), 
1.86-4.23 (m, 7H, furan).
RESULTS AND DISCUSSION
The synthesis of amide derivatives of 1-benzyl-
theobromine-8-thioglicolic acid consists of bromi-
nating of theobromine (1) to obtain 8-bromotheo-
bromine (2). Its further interaction with benzyl chlo-
ride resulted in synthesis of 1-benzyl-8-bromotheo-
bromine (3). The next stage is the formation of the 
corresponding 1-benzyltheobromine-8-thioglicolic 
acid (4) by interaction of (3) with thioglycolic acid. 
The necessary for the aminolysis ester derivative (5) 
was obtained by esterification. The targeted struc-
tures were synthesized by classical aminolysis. The 
total synthetic scheme for the preparation of the ini-
tial methyl ester of 1-benzyltheobromine-8-thiogli-
colic acid is presented on Fig. 1.
The synthesis of 8-bromotheobromine (2) was 
carried out via oxidative bromination of theobro-
mine (1) according to the literary method (14), based 
on application of HBr and H2O2 in glacial acetic acid. 
Under these conditions the reaction due 4 hours and 
the corresponding yield of re-crystallized 8-bro-
motheobromine was 80 -85%. 
The next stage of our synthetic sequence is ob-
taining 1-benzyl-8-bromotheobromine (3). The syn-
thesis was performed under phase-transfer catalysis 
conditions, whereat aliquat 336 was used as catalyst. 
The corresponding reaction is presented on Fig. 2.
Based on previous experiments improving the 
reaction conditions (20) we led the reaction in water/
ethanol media, in the presence of sodium hydroxide. 
At these conditions no side reaction was observed 
and the reaction time was shortened up to 1 and a 
half hour with yield of 81%. The next stage is for-
mation of the corresponding 1-benzyltheobromine-
8-thioglicolic acid (4) by interaction of (3) with thio-
glycolic acid. The necessary for the aminolysis, ester 
derivative (5), was obtained by classical esterification 
(23).
The targeted amide derivatives were synthe-
sized by interaction of the corresponding amine and 
the methyl ester of 1-benzyltheobromine-8-thiogli-
colic acid, according to Fig. 3.
The aminolysis of the compounds was per-
formed in melt, with 2:1 correlation of the reactants 
for the selected amine. For all the synthesis the re-
action mixture was heated in glycerin bath until the 
methyl ester of 1-benzyltheobromine-8-thioglicolic 
acid was melted, which formed melt with the applied 
amine, and this temperature is maintained until the 
Fig. 1. General scheme of synthesis of methyl ester of 1-benzyltheobromine-8-thioglicolic acid
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end of the reaction. The reaction times are between 
20 min to one hour, the temperature vary from 110 to 
130oC and the yields are in range of 61 to 81,2%.
Using the above described methods five amide 
derivatives of 1-benzyltheobromine-8-thioglicolic 
acid were synthesized. The reaction conditions and 
the corresponding reaction time and yield for each of 
the targeted products are given in Table 1. 
It is clearly seen in Table 1 that target products 
7a-e are obtained with good yields and purity, where-
as 7a is obtained with highest yield. The structure of 
the newly synthesized compounds was proven by el-
emental analysis, IR and 1H-NMR spectroscopy.
The obtained structures are white crystalline 
powders, soluble in organic solvents (chloroform, 
benzene, dimethylformamide) and practically in-
soluble in water. The obtained amides are stable to 
hydrolysis under acidic or alkali conditions, close to 
physiological pH and temperatures about 40oC. Un-
der these conditions no hydrolysis is observed for a 
period of more than 20 hours.
The FT-IR spectra of the studied N-substituted 
1-benzyltheobromine-8-thioglycolacetamides 7a-e 
in the region of the 4000 – 400 cm-1 exhibit several 
characteristic bands. The two strong bands at about 
1680 to 1702 cm-1 are ascribable to the streching vi-
bration of two carbonyl groups in the xanthine ring. 
The vibrational band recorded at 1716 – 1725 cm-1 
belongs to the carbonyl in the amide moiety in the 
side chain (amide I), while the band at 1595 – 1605 
Fig. 2. Synthesis of 1-benzyl-8-bromotheobromine
Fig. 3. General scheme for synthesis of the targeted amide derivatives of 1-benzyltheobromine-8-thioglicolic acid
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cm-1 in the spectra of 7a,e corresponds to streching 
vibration N-H from the same residue (amide II). This 
band do not present in the spectra of the other com-
pounds since they are tertiary amides. The band at 
about 1550 cm-1 belongs to the streching vibration of 
C=C bonds in xanthine ring.
More detailed information about the structure 
of compounds 7a-e was provided by the 1H NMR 
spectra. Thus, the strong singlets at 3.45 3.48 and 
3.80 3.82 ppm in the spectrum of the studied com-
pounds correspond to N-methyl protons at position 
3 and 7. The signal of the N-methylene group from 
1-benzyltheobromine-8-thioglycolic acid at position 
8 appears at 3.70 ppm as broad singlet. The signals 
of methylene protons from the benzyl side chain at 
position 1 form strong singlet at 4.80 ppm. The sig-
nals of the aromatic protons from benzyl side chain 
at position 1 in the spectra of 7a-e correspond to 
complicated multiplets between 7.24 and 7.36 ppm, 
but the integral curves correspond to the exact num-
ber of the protons. The signals of methylene protons 
from the cyclohexyl residue of 7a-d form broad mul-
tiplet between 1.68 and 1.39 ppm. The methyne pro-
ton from the cyclohexyl residue forms a multiplet 
with weak intensity between 3.85 and 3.80 ppm. In 
the spectrum of 7d there is a strong singlet at 3.75 
ppm that corresponds to N-methyl protons in the 
side chain. The ethyl group in the spectrum of 7b ap-
pears as multiplet at 3.26 ppm and strong triplet at 
1.22 ppm. There are some differences between spec-
trum of 7e and these of 7a-d where protons of tetra-
hydrofurylmethyl residue form broad complex mul-
tiplets between 1.86 and 4.23 ppm. The values of the 
chemical shifts of the protons registered by 1H NMR 
spectra were compared with simulated values (2,4, 
6,7). We observed only small deviations of comput-
ed from experimental values, due to an impossibility 
to render an account of influence of the solvent. Re-
gardless, the simulated 1H NMR spectra are in good 
correlation with the experimental ones.
Druglikeness prediction
There are many approaches that assess a com-
pound’s “druglikeness”, partially based on topologi-
cal descriptors, fingerprints of MDL structure keys 
or other properties. In addition the biological activi-
ty is also usually a function of the complex influence 
of a number of molecular descriptors. In some cases, 
an underlayment of a certain parameter is possible, 
whereas the hydrophobicity of the compounds, usu-
ally expressed as LogP, appears to be a key parameter 
for determination of compounds druglikeness. 
In the present work we have applied two ap-
proaches in an attempt to evaluate the drug-like 
properties of the newly synthesized by us amide de-
rivatives of 1-benzyltheobromine-8-thioglicolic acid: 
the Lipinski’s Rule of Five limitations and the OSIRIS 
Property Explorer evaluation score.
Determination of Lipinski’s Rule of Five 
parameters
Lipinski’s rule of five also known as the Rule of 
five (RO5) is a rule of thumb to evaluate druglikeness 
or determine if a chemical compound with a cer-
tain pharmacological or biological activity has prop-
erties that would make it a likely orally active drug 
in humans. The rule was formulated by Christopher 
A. Lipinski in 1997, based on the observation that 
most medication drugs are relatively small and lipo-
philic molecules (16, 17). The rule describes molecu-
lar properties important for a drug’s pharmacokinet-
ics in the human body, including their absorption, 
distribution, metabolism, and excretion (“ADME”). 
However, the rule does not predict if a compound is 
pharmacologically active. Candidate drugs that con-
firm to the RO5 tend to have lower attrition rates 
compound temperature oС reaction time min. Yield % Melting point oC
7a 120° 20 81,2 180-183
7b 130° 60 62 149-151
7c 130° 40 64 130-134
7d 115° 60 61 157-160
7e 110° 60 66 160-161
Table 1. Reaction conditions and the corresponding reaction time and yield and melting points for the synthesis of each 
of the targeted products
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ID Structure
Lipinski’s Rule of Five Parameters
Log P MW n (O, N) n (OH,NH)
TPSA %ABS
7a 3.587 441.557 8 1 90.93 77.63
7b 4.208 469.611 8 0 82.14 80.66
7c 5.737 523.703 8 0 82.14 80.66
7d 3.832 455.584 8 0 82.14 80.66
7e 2.056 443.529 9 1 100.16 74.44
TB -0.951 180.167 6 1 72.69 83.92
Table 2. Structure and some molecular parameters of the newly synthesized amide derivatives of 1-benzyltheobromine-
8-thioglicolic acid
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during clinical trials and hence have an increased 
chance of reaching the market (17,18). Lipinski’s rule 
states that, in general, an orally active drug has no 
more than one violation of the following criteria: 1) 
no more than 5 hydrogen bond donors (nitrogen or 
oxygen atoms with one or more hydrogen atoms); 2) 
not more than 10 hydrogen bond acceptors (nitrogen 
or oxygen atoms); 3) a molecular mass less than 500 
daltons and 4) an octanol-water partition coefficient 
logP not greater than 5.
In the present work, the Lipinski’s parameters 
were calculated with the help of the web based serv-
er Molinspiration Cheminformatics (31). This soft-
ware offers broad range of cheminformatics software 
tools supporting molecule manipulation and pro-
cessing, including SMILES and SDfile conversion, 
normalization of molecules, generation of tautomers, 
molecule fragmentation, calculation of various mo-
lecular properties needed in QSAR, molecular mod-
eling and drug design, high quality molecule depic-
tion, molecular database tools supporting substruc-
ture and similarity searches (31). 
Using this software we calculated the values of 
the Lipinski’s Rule of Five parameters and the ob-
tained results are presented in Table 2.
From the performed calculation is obvious, that 
only one structure violates the Lipinski’s Rule of Five 
parameters – 7c, which makes it unsuitable for fur-
ther structural optimizations. 
In addition we determined the extension of ab-
sorption, expressed by the percentage of absorption. 
The absorption percent was calculated (30) using the 
expression: %ABS = 109 – 0.345PSA.
Evaluation of drug-like properties of the new 
synthesized compounds, using the OSIRIS Proper-
ty Explorer tool.
The OSIRIS Property Explorer used in this pub-
lication for druglikeness prediction tool is an inte-
gral part of Actelion’s inhouse substance registration 
system (28). The prediction process relies on a pre-
computed set of structural fragment that gives pre-
liminary information on a number of drug-relevant 
properties, like druglikeness and/or toxicity alerts. 
Evaluation of druglikeness
The synthesized by us new amide derivatives of 
1-benzyltheobromine-8-thioglicolic acid were eval-
uated for druglikeness, using the web based serv-
er OSIRIS Property Explorer (32). The correspond-
ing molecule’s druglikeness was assessed by two pa-
rameters: Fragment Based Druglikeness and Drug 
Score.
Fragment Based Druglikeness 
This parameter is calculated with the following 
equation summing up score values of those fragments 
that are present in the molecule under investigation:
A positive value states that the analyzed mole-
cule contains predominatly fragments which are fre-
quently present in commercial drugs (33). 
Drug Score
The drug score combines druglikeness, cLogP, 
logS, molecular weight and toxicity risks in one 
handy value that may be used to judge the com-
pound’s overall potential to qualify for a drug. This 
value is calculated by multiplying contributions of 
the individual properties with the first equation:
where: ds is the drug score. si are the contributions 
calculated directly from of cLogP, logS, molweight 
and druglikeness (pi) via the second equation which 
describes a spline curve. 
Parameters a and b are (1, -5), (1, 5), (0.012, -6) 
and (1, 0) for cLogP, logS, molweight and druglike-
ness, respectively. ti are the contributions taken from 
the 4 toxicity risk types. The ti values are 1.0, 0.8 and 
0.6 for no risk, medium risk and high risk, respective-
ly (34). 
The corresponding values of the computational 
analysis are presented in Table 3.
From the performed evaluation was established, 
that compound 7e shows a highest drug like prop-
erties with Fragment Based Druglikeness score of 
2.58 and total Drug score of 0.43.
Evaluation of toxicity risks
The fragment lists, necessary for evaluation of 
toxicity risks, were created by rigorously shredder-
ing all compounds of the RTECS database known 
to be active in a certain toxicity class (e.g. mutagen-
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icity). During the shredding any molecule was first 
cut at every rotatable bonds leading to a set of core 
fragments. These in turn were used to reconstruct all 
possible bigger fragments being a substructure of the 
original molecule. Afterwards, a substructure search 
process determined the occurrence frequency of any 
fragment (core and constructed fragments) within 
all compounds of that toxicity class (35).
Due to the high structural similarity in the 
evaluated group of compounds it was determined, 
that for all the compounds a high risk of tumorigen-
ic toxicity may be predicted, which is result from the 











may be a reason for the expected performance from 
structure 7d of medium risk of mutagenicity.
CONCLUSION
The synthesis of 1-benzyltheobromine-8-thio-
glycolacetamides consists of bromination of theobro-
mine to obtain the corresponding 8-bromotheobro-
mine, its benzylation at position 1 in the presence of 
aliquat 366 as phase transfer catalist and further in-
teraction with thioglycolic acid with subsequent es-
terification with methanol. The corresponding am-
ide derivatives are further obtained by aminolysis of 
the methyl ester with the desired amine. The newly 
synthesized 7a-e are crystal compounds with white 
to very pale-yellow colour, soluble in DMF, sparingly 
soluble in alcohol and insoluble in water. The struc-
tures of the studied compounds were established by 
FTIR, 1H NMR spectral data. In order to estimate the 
drug-likeness of compounds 7a-e, a theoretical cal-
culation of some molecular descriptors was made us-
ing two approaches: the Lipinski’s Rule of Five and 
the OSIRIS Property Explorer evaluation score. The 
comparison of the calculated results indicate that 
only one compound violates the Lipinski’s Rule of 
Five parameters – 7c, which makes is unsuitable for 
further structural optimizations. On the other hand 
compound 7e shows a highest drug like properties 
with Fragment Based Druglikeness score of 2.58 
and total Drug score of 0.43 which are better than 
the same scores of parent compound theobromine. 
For all of the compounds a good oral bioavailability 
manifestation may be expected. The possible phar-
macological effects and clarification of their poten-
tial as prodrugs will be further estimated.
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